• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>European Heart Journal: The Journal of the European Society of Cardiology >Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on antiplatelet drugs reistance appointed by the Section of Cardiovascular Interventios of the Polish Cardiac Society
【24h】

Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on antiplatelet drugs reistance appointed by the Section of Cardiovascular Interventios of the Polish Cardiac Society

机译：口服抗血小板药物反应的个体差异：波兰心脏学会心血管介入科任命的抗血小板药物耐药性工作组的立场文件，由心血管介入科指定的抗血小板药物耐药性工作组认可波兰心脏病学会

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Oral antiplatelet drugs are a cornerstone of modern pharmacotherapy in cardiovascular atherothrombotic diseases. The efficacy of acetylsalicylic acid (ASA, aspirin) and clopidogrel in decreasing the risk of adverse events in coronary heart disease patients has been well established in the past 20 years. Despite chronic oral antiplatelet therapy, a number of atherothombotic events continue to occur. In recent years, a number of reports in the literature have shown possible relationships between residual platelet activity, as measured with a variety of laboratory tests, and clinical outcome, raising the possibility that 'resistance' to oral antiplatelet drugs may underlie many such clinical adverse events. The present position paper, conveyed within a group of clinical cardiologists with expertise in thrombosis appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, has been further elaborated and endorsed by the Working Group on Thrombosis of the European Society of Cardiology. It aims at summarizing the main findings in this complex area, issuing opinions in cases of high controversy, and fostering future research in this area to obtain reliable laboratory and clinical data for the resolution of the many problems still open.
机译：口服抗血小板药物是现代药物治疗心血管动脉粥样硬化性疾病的基石。在过去的20年中，已经确立了乙酰水杨酸（ASA，阿司匹林）和氯吡格雷在降低冠心病患者不良事件风险中的功效。尽管进行了慢性口服抗血小板治疗，但许多动脉粥样硬化事件继续发生。近年来，文献中的许多报告显示，通过各种实验室测试测得的残余血小板活性与临床结局之间可能存在联系，从而增加了对口服抗血小板药物的“耐药性”可能是许多此类临床不良事件的基础。事件。本立场文件由波兰心脏病学会心血管介入科任命的具有血栓形成专长的临床心脏病专家小组传达，并得到了欧洲心脏病学会血栓形成工作组的进一步阐述和认可。它旨在总结该复杂领域的主要发现，在争议较大的情况下发表意见，并促进该领域的未来研究，以获得可靠的实验室和临床数据，以解决仍然存在的许多问题。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号